[
  {
    "oncogenic": "Likely Oncogenic",
    "drugDescription": "Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1 and is NCCN-listed as a category 2A treatment recommendation for patients with non-small cell lung cancer (NSCLC) who have ROS1 rearrangements. In a Phase II study of ceritinib in 32 patients with NSCLC harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI= 45 - 77) with one patient having a complete response and nineteen patients having a partial response (PMID: 28520527).",
    "cancerTypes":
    [
      {
        "id": 876,
        "subtype": "",
        "code": "",
        "color": "Gainsboro",
        "mainType": "Non-Small Cell Lung Cancer",
        "level": 0,
        "tissue": "Lung",
        "tumorForm": "SOLID"
      }
    ],
    "excludedCancerTypes":
    [],
    "variant":
    {
      "gene":
      {
        "entrezGeneId": 6098,
        "hugoSymbol": "ROS1",
        "oncogene": true,
        "grch37Isoform": "ENST00000368508",
        "grch37RefSeq": "NM_002944.2",
        "grch38Isoform": "ENST00000368508",
        "grch38RefSeq": "NM_002944.2",
        "geneAliases":
        [
          "MCF3",
          "ROS",
          "c-ros-1"
        ],
        "genesets":
        [],
        "tsg": false
      },
      "consequence":
      {
        "term": "NA",
        "isGenerallyTruncating": false,
        "description": "NA"
      },
      "alteration": "Fusions",
      "name": "Fusions",
      "refResidues": null,
      "proteinStart": -1,
      "proteinEnd": 100000,
      "variantResidues": null,
      "referenceGenomes":
      [
        "GRCh38",
        "GRCh37"
      ]
    },
    "level": "2",
    "fdaLevel": "Fda2",
    "drug":
    [
      "Ceritinib"
    ],
    "drugPmids":
    [
      "28520527"
    ],
    "drugAbstracts":
    []
  },
  {
    "oncogenic": "Likely Oncogenic",
    "drugDescription": "Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI= 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI= 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI= 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI= 12.9-24.0) (PMID: 29596029).",
    "cancerTypes":
    [
      {
        "id": 876,
        "subtype": "",
        "code": "",
        "color": "Gainsboro",
        "mainType": "Non-Small Cell Lung Cancer",
        "level": 0,
        "tissue": "Lung",
        "tumorForm": "SOLID"
      }
    ],
    "excludedCancerTypes":
    [],
    "variant":
    {
      "gene":
      {
        "entrezGeneId": 6098,
        "hugoSymbol": "ROS1",
        "oncogene": true,
        "grch37Isoform": "ENST00000368508",
        "grch37RefSeq": "NM_002944.2",
        "grch38Isoform": "ENST00000368508",
        "grch38RefSeq": "NM_002944.2",
        "geneAliases":
        [
          "MCF3",
          "ROS",
          "c-ros-1"
        ],
        "genesets":
        [],
        "tsg": false
      },
      "consequence":
      {
        "term": "NA",
        "isGenerallyTruncating": false,
        "description": "NA"
      },
      "alteration": "Fusions",
      "name": "Fusions",
      "refResidues": null,
      "proteinStart": -1,
      "proteinEnd": 100000,
      "variantResidues": null,
      "referenceGenomes":
      [
        "GRCh38",
        "GRCh37"
      ]
    },
    "level": "1",
    "fdaLevel": "Fda2",
    "drug":
    [
      "Crizotinib"
    ],
    "drugPmids":
    [
      "30980071",
      "25264305",
      "29596029"
    ],
    "drugAbstracts":
    []
  },
  {
    "oncogenic": "Likely Oncogenic",
    "drugDescription": "Repotrectinib is an orally bioavailable tyrosine kinase inhibitor that targets ROS1. In the Phase I/II TRIDENT-1 study of repotrectinib in 171 patients with ROS1-fusion-positive non-small lung cancer (NSCLC), an overall objective response rate of 79% was found in patients who had not previously received a ROS1 tyrosine kinase inhibitor treatment. For patients previously treated with a ROS1 tyrosine kinase inhibitor, overall response rates were 38% if the patient did not previously receive chemotherapy, 42% if the patient did previously receive chemotherapy and 28% if the patient previously received two different ROS1 tyrosine kinase inhibitors (Abstract: Cho et al. Abstract# 2LBA, EJC 2022. https://www.ejcancer.com/article/S0959-8049(22)00812-7/fulltext).",
    "cancerTypes":
    [
      {
        "id": 876,
        "subtype": "",
        "code": "",
        "color": "Gainsboro",
        "mainType": "Non-Small Cell Lung Cancer",
        "level": 0,
        "tissue": "Lung",
        "tumorForm": "SOLID"
      }
    ],
    "excludedCancerTypes":
    [],
    "variant":
    {
      "gene":
      {
        "entrezGeneId": 6098,
        "hugoSymbol": "ROS1",
        "oncogene": true,
        "grch37Isoform": "ENST00000368508",
        "grch37RefSeq": "NM_002944.2",
        "grch38Isoform": "ENST00000368508",
        "grch38RefSeq": "NM_002944.2",
        "geneAliases":
        [
          "MCF3",
          "ROS",
          "c-ros-1"
        ],
        "genesets":
        [],
        "tsg": false
      },
      "consequence":
      {
        "term": "NA",
        "isGenerallyTruncating": false,
        "description": "NA"
      },
      "alteration": "Fusions",
      "name": "Fusions",
      "refResidues": null,
      "proteinStart": -1,
      "proteinEnd": 100000,
      "variantResidues": null,
      "referenceGenomes":
      [
        "GRCh38",
        "GRCh37"
      ]
    },
    "level": "3A",
    "fdaLevel": "Fda3",
    "drug":
    [
      "Repotrectinib"
    ],
    "drugPmids":
    [],
    "drugAbstracts":
    [
      {
        "link": "https://www.ejcancer.com/article/S0959-8049(22",
        "abstract": "Cho et al. Abstract# 2LBA, EJC 2022"
      }
    ]
  },
  {
    "oncogenic": "Likely Oncogenic",
    "drugDescription": "Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is NCCN-listed as a category 2A recommended subsequent therapy option for patients with ROS1-rearrangement-positive non-small cell lung cancer (NSCLC) who progressed on entrectinib, crizotinib or ceritinib. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive NSCLC, thirteen of 21 tyrosine kinase inhibitor-naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI= 38-82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI= 21-52)(PMID: 31669155).",
    "cancerTypes":
    [
      {
        "id": 876,
        "subtype": "",
        "code": "",
        "color": "Gainsboro",
        "mainType": "Non-Small Cell Lung Cancer",
        "level": 0,
        "tissue": "Lung",
        "tumorForm": "SOLID"
      }
    ],
    "excludedCancerTypes":
    [],
    "variant":
    {
      "gene":
      {
        "entrezGeneId": 6098,
        "hugoSymbol": "ROS1",
        "oncogene": true,
        "grch37Isoform": "ENST00000368508",
        "grch37RefSeq": "NM_002944.2",
        "grch38Isoform": "ENST00000368508",
        "grch38RefSeq": "NM_002944.2",
        "geneAliases":
        [
          "MCF3",
          "ROS",
          "c-ros-1"
        ],
        "genesets":
        [],
        "tsg": false
      },
      "consequence":
      {
        "term": "NA",
        "isGenerallyTruncating": false,
        "description": "NA"
      },
      "alteration": "Fusions",
      "name": "Fusions",
      "refResidues": null,
      "proteinStart": -1,
      "proteinEnd": 100000,
      "variantResidues": null,
      "referenceGenomes":
      [
        "GRCh38",
        "GRCh37"
      ]
    },
    "level": "2",
    "fdaLevel": "Fda2",
    "drug":
    [
      "Lorlatinib"
    ],
    "drugPmids":
    [
      "31669155"
    ],
    "drugAbstracts":
    []
  },
  {
    "oncogenic": "Likely Oncogenic",
    "drugDescription": "Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397).",
    "cancerTypes":
    [
      {
        "id": 876,
        "subtype": "",
        "code": "",
        "color": "Gainsboro",
        "mainType": "Non-Small Cell Lung Cancer",
        "level": 0,
        "tissue": "Lung",
        "tumorForm": "SOLID"
      }
    ],
    "excludedCancerTypes":
    [],
    "variant":
    {
      "gene":
      {
        "entrezGeneId": 6098,
        "hugoSymbol": "ROS1",
        "oncogene": true,
        "grch37Isoform": "ENST00000368508",
        "grch37RefSeq": "NM_002944.2",
        "grch38Isoform": "ENST00000368508",
        "grch38RefSeq": "NM_002944.2",
        "geneAliases":
        [
          "MCF3",
          "ROS",
          "c-ros-1"
        ],
        "genesets":
        [],
        "tsg": false
      },
      "consequence":
      {
        "term": "NA",
        "isGenerallyTruncating": false,
        "description": "NA"
      },
      "alteration": "Fusions",
      "name": "Fusions",
      "refResidues": null,
      "proteinStart": -1,
      "proteinEnd": 100000,
      "variantResidues": null,
      "referenceGenomes":
      [
        "GRCh38",
        "GRCh37"
      ]
    },
    "level": "1",
    "fdaLevel": "Fda2",
    "drug":
    [
      "Entrectinib"
    ],
    "drugPmids":
    [
      "28183697"
    ],
    "drugAbstracts":
    [
      {
        "link": "https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397",
        "abstract": "Braud et al. Abstract# 64P, ESMO 2019"
      },
      {
        "link": "https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060",
        "abstract": "Drilon et al. Abstract# CT060, AACR 2017"
      }
    ]
  }
]
